Read time: 2 minutes
By: McKesson Health Systems Editorial Team
Our most-downloaded content by health system teams in September 2023 includes a podcast discussing the untapped benefits of Patient Assistance Programs (PAP), including expanding patient access and reducing treatment delays, a featured article in collaboration with Becker’s Hospital Review that discusses rising challenges and cost pressures in today’s complex market, and a closer look at what Teva’s recently imposed pricing restrictions may mean for the 340B program. Click our recommended reads to learn more on Prescribed Perspectives about how partnering with McKesson can help your health system achieve more.
Prescribed Perspectives Podcast: The Untapped Benefits of Patient Assistance Programs
Our experts discuss how patient assistant programs can help health systems tap into potential benefits, including patient access and reduced treatment delays.
Managing Increased Cost Pressures for Health Systems so You Can Achieve More
New payment models and a focus on patient-centered care show real promise to fundamentally change the way care is delivered. At the same time, the current cost pressures threaten the financial viability of hospitals and systems large and small. Read more about rising challenges and managing cost pressures in McKesson’s latest article in collaboration with Becker’s Hospital Review.
Nothing Generic About It – Is Teva’s Exit a Turning Point for the 340B Program?
With 23 drug manufacturers already having restricted 340B pricing to contract pharmacies at the time, Teva’s June 2023 announcement that they, too, would begin imposing 340B-pricing restrictions was not altogether unprecedented – but it does set the stage for what could be a paradigm shift in the 340B exit trend.
Share
Post
Post
Email